## Nestlé India (NESIND)

CMP: ₹ 19002 Target: ₹ 20450 (8%)

Target Period: 12 months

November 1, 2021

## Sustainable growth; elevated margins to continue...

About the stock Nestlé India (NIL) is the largest food company in India with over ₹ 13000 crore of sales. It is broadly present in infant & baby food products, noodles, chocolates & beverages categories. In the last five years, the company has forayed into newer categories and launched more than 90 new products.

 The company has nine manufacturing facilities including a new plant in Sanand, Gujarat that got commissioned during the quarter. Its major brands include Maggi, Nescafe, KitKat, Cerelac among others

**Key Highlights of analyst meet:** We attended Nestlé's analyst meet on October 29, 2021. The management reiterated its strategies & focal points.

- Continue to focus on volume growth through penetration
- Thrust on innovations & strong pipeline of new products
- Effort to enhance rural reach to 1.2 lakh villages by 2024
- · Accelerating footprint in new emerging trade channels

What should investors do? Nestlé India's share price has given return of 185% in the last five years (from ₹ 6654 in November 2016 to ₹ 19002 in October 2021).

• We continue to maintain our HOLD rating on the stock

Target Price and Valuation: We value the stock at ₹ 20450, valuing the business at 65x FY24 earnings

## Key triggers for future price performance:

- The company is undertaking a capex of ₹ 2600 crore in the next three to four years to expand the capacity of its existing products
- NIL is increasing its rural footprint from 0.9 lakh villages to 1.2 lakh villages in the next four years
- With the reduction in Covid-19 cases & vaccination drive, urban demand is likely to pick up. The product portfolio of NIL is urban centric
- Commissioning of Sanand facility would aid revenue growth in core brands given packaged foods saw high demand in the last 18 months

Alternate Stock Idea: We also like Zydus Wellness in our FMCG coverage.

- It is growing at a steady pace in nascent categories with strong presence in health, nutrition space & margin expansion possibilities
- Trading at significant discount to FMCG peers. BUY with a TP of ₹ 2,800




HOLD



Particulars	
Particulars (₹ crore)	Amount
Market Capitalization	183217
Total Debt (CY20)	97.5
Cash & Investments (CY20)	2,880.2
EV	180,434.5
52 week H/L (₹)	20599 / 15900
Equity capital	96.4
Face value (₹)	10.0

Shareholding pattern													
(in % )	Dec-20	Mar-21	Jun-21	Sep-21									
Promoter	62.8	62.8	62.8	62.8									
FII	12.8	12.3	12.4	12.3									
DII	7.7	7.9	7.9	8.0									
Others	16.7	17.0	16.9	16.9									



## Recent event & key risks

- NIL's ninth plant in Sanand was commissioned during the quarter
- Key Risk: (i) Incessant increase in commodity costs to pressurise margins (ii) Strong growth in core categories to be upside risk

#### **Research Analyst**

Sanjay Manyal sanjay.manyal@icicisecurities.com

Key Financial Summary			5 Year CAGR				
Key Financials	CY19	CY20	(CY15-CY20)	CY21E	CY22E	CY23E	CAGR (CY20-23E)
Net Sales	12295.3	13290.2	10.3	14763.6	16145.7	17822.4	10.3%
EBITDA	2864.3	3201.5	14.4	3656.9	4055.2	4555.1	12.5%
EBITDA Margin %	23.3	24.1		24.8	25.1	25.6	
Net Profit	1969.6	2082.4	29.9	2410.0	2695.4	3029.6	13.3%
EPS (₹)	204.27	215.97	29.9	249.95	279.55	314.21	13.3%
P/E	93.0	88.0		76.0	68.0	60.5	
RoNW %	101.9	86.5		87.8	86.3	83.1	
RoCE (%)	56.9	50.9		54.9	56.4	57.5	

Source: Company, ICICI Direct Research

## Key takeaways from analyst meet

# Analyst meet update: Emphasis on Rurban growth, innovations, capacity enhancement of core categories

- NIL has commissioned its ninth manufacturing facility in Sanand, Gujarat.
   This is digitally the most advanced factory. The investment in the factory is part of the bigger capacity expansion plan of ₹ 2600 crore over the next three to four years
- The company has seen revenue growth of 11% led by 9.3% volume & mix CAGR over the last four years (CY16-20). Operating profit saw 16.6% CAGR growth with margins expansion by 410 bps in the similar period. Net profit growth has been 29.9%
- In 2021 (YTD Sept), NIL has been sustaining its growth with revenue growth of 10.7%, operating profit growth of 12.6%, margins of 22.6% (40 bps increase) & net profit growth of 9.9%
- Milk product segment (contributes 42.8% to sales) grew a slower 1% in CY21 (YTD September) with pantry loading in base year during lockdown. Prepared dishes (contributes 32.1%) grew 20.9% led by increase in home consumption & lack of mobility. Chocolate portfolio (contributes 4.9%) grew by 22.3% & beverage (contribute 10.2%) grew 15.7%
- Thrust on innovation is greater than ever in last five years. It has launched 90 new products in the period. Further, 10 new products are in the pipeline. The new products contribution to sales has increased from 1.5% in 2016 to 5% in 2021 (YTD September)
- Media spend behind brands has increased 1.35x between 2016 and 2020.
   NIL is maintaining a healthy mix in investing behind core brands & new products. Further, it is improving efficiencies in buying media, enhancing digital footprint, targeting communication through clusters & investing in brand equity rather than short term promotions
- Within marketing spends, share of consumer promotion has gone down from 43% to 18% while media spends have gone up from 57% to 82%.
   Further spends on media creation are coming down and media airing is going up. Digital media spends have increased by 2.9x in last four years
- Though 85% of the company's sales comes from tradition channels (GT, CSD), the share of e-commerce sales has increased 8x in last five years.
   E-commerce contribution to sales was 0.6% in 2016 and was 5.1% in 2021 (YTD September). The current year growth in e-commerce channel sales is 65%
- NIL's distribution reach has increased by 25% to 5 million outlets between 2016 and 2020. However, its direct reach is only grown from 1.3 million to 1.4 million outlets. It is growing its distribution in rural regions through wholesales channel network
- Rurban (rural + smaller towns) sales has grown by 16% in 2021 (YTD September). The company is looking to accelerate growth in Rurban regions through customised portfolio, localised communication, increasing visibility & building consumer connect
- The company is looking to increase its rural footprint from current 1.0 lakh villages to 1.2 lakh villages by 2024 through wholesales hubs & smaller distributors
- Inflation is high in four out of six major commodities for company. Milk prices, SMP & packaging cost is up 20-30% in last five years whereas edible oil prices are up a steep 70% in the last five years. Most of the commodities are at a 10 year high. This inflation is here to stay in the medium term


- The management believes the consumer is willing to pay more for trustworthy, better nutrition brands
- Regarding the disconnect between increasing village network & stagnant direct reach, the management said that in hinterland the incremental cost of distribution is more than incremental return on distribution therefore it is going for auxiliary (wholesales led) distribution model in rural areas
- The company was unable to concentrate on Milo & NesPlus brands given its
  focus remains in protecting core categories during pandemic. NIL would be
  looking to unveil distinct growth engines for these brands
- Nestlé's portfolio is 30% popularly priced products, around 50% is premium offerings and the rest is the mainstream. Hence, its brands not just represent premium products and many of its products can find resonance in smaller market
- Exports contributes 5% to total sales. However, NIL consider exports as a sourcing opportunity in nearby countries. Moreover, exports are largely catering to the Indian diaspora
- The company is looking to enter two to three categories, which can give extra growth (over & above sustainable ~10%) with the expectation of maintaining similar margins. While foraying in a category, the company looks into the longevity of the product & sustainable growth
- The growth in dairy whiteners was impacted adversely during pandemic given distribution in some of geographies like Kerala, North East (fair amount of dairy whiteners are sold in these regions) were disrupted
- Cost rationalisation measure programme 'Shark' has helped it save ₹ 200 crore every year from last four years. Under this programme, production loss came down by 42%

Exhibit 1: Peer Comp	arisor	ı																		
Sector / Company	CMP	TP		M Cap	Sales	Sales growth (%)		EBITDA Margins (%)			P/E(x)			ı	RoE (%)			RoCE (%)		
Sector / Company	(₹)	(₹)	Rating	(₹ Cr)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	
Hindustan Unilever (HINLEV)	2393	2750	Hold	582416	12.9	9.1	8.4	25.6	26.2	26.3	63.0	55.9	51.0	19.5	21.5	23.0	25.0	27.6	29.5	
Varun Beverage (VARBEV)	849	1020	Buy	36780	31.3	10.4	10.0	19.5	20.26	19.96	52.98	41.78	37.48	17.16	18.89	19.05	19.56	23.44	26.29	
Nestle (NESIND)	19002	20450	Hold	183217	11.1	9.4	10.4	24.8	25.1	25.6	76.0	68.0	60.5	87.8	86.3	83.1	54.9	56.4	57.5	
Tata Consumer (TATGLO)	810	910	Buy	72703	8.9	8.4	9.7	13.9	14.6	14.9	67.0	56.0	48.6	7.2	8.3	9.2	8.9	9.9	10.8	

Source: Company, ICICI Direct Research


The growth in Nestlé was largely contributed by volumes and change in product mix. The company commissioned its ninth plant in Sanand, Gujarat during the quarter. We believe NIL would be able to resolve capacity challenges in core categories with the commissioning of new facility given noodles, chocolates & beverage categories are witnessing stronger traction. Further, the company is increasing its penetration levels in rural India by increasing its distribution reach in hinterland. The e-commerce channel has also become important channel for packaged foods category for NIL and is growing faster than other channels. Though inflationary pressure related to crude & edible oil remains high, we believe the company would be able to maintain its margins in medium term with cost rationalisation measures & mix changes. We remain positive on Nestlé's growth prospects, going forward. The present valuation multiples capturing business strength & longer term sustainable growth (10-11%). However, any future upgrade in growth rates (through newer categories, new products & distribution reach enhancement) would warrant the change in stance. We maintain our **HOLD** rating on the stock with a target price of ₹ 20450/share.

## Exhibit 2: New product contribution to sales



Source: ICICI Direct Research, Company

## Exhibit 3: Consistent media support to brand




Source: ICICI Direct Research, Company

## Exhibit 4: Ecommerce channel sales up 8x in five years




Source: ICICI Direct Research, Company

## Exhibit 5: Direct, Indirect & total distribution reach



Source: ICICI Direct Research, Company

## Exhibit 6: Rurban growth in last five years




Source: ICICI Direct Research, Company


## Exhibit 7: Rural distribution network



Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company



Source: ICICI Direct Research, Company



Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company








Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company



Source: ICICI Direct Research, Company



Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company

#### Exhibit 21: Volume growth to drive revenue 15 1 4 0.1 10 5 0 -5 -10 CY17 **CY18** CY19 CY20 CY21E CY22E CY23E ■ Volume Growth (%) ■ Price Growth (%)

Source: ICICI Direct Research, Company

## Milk products & nutrition



Source: ICICI Direct Research, Company


#### Exhibit 23: Revenue growth to be mix of volume & price growth 12 10 8 6 4 6.0 2 0 -2 CY17 **CY18** CY19 **CY20** CY21E CY22E CY23E ■Volume growth (%) Realisation growth(%)

Source: ICICI Direct Research, Company

## **Beverages**




Source: ICICI Direct Research, Company




Source: ICICI Direct Research, Company

## **Prepared dishes**



Source: ICICI Direct Research, Company

# Exhibit 27: Strong volume growth trend



Source: ICICI Direct Research, Company


## **Chocolate & confectionery**

## Exhibit 28: Sales to gain traction, going forward




Source: ICICI Direct Research, Company

## Exhibit 29: Volumes to recover in CY21E




Source: ICICI Direct Research, Company

## Exhibit 30: EBITDA margin to remain at elevated levels



Source: ICICI Direct Research, Company

## Exhibit 31: PAT to grow at 13.3% CAGR over CY20-23E



Source: ICICI Direct Research, Company

Exhibit 32:	: Valuations							
	Sales	Growth	EPS	Growth	PE	EV/EBITDA	RoNW	RoCE
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)
CY20	13290.2	8.1	216.0	5.7	83.3	53.6	86.5	50.9
CY21E	14763.6	11.1	249.9	15.7	72.0	47.2	87.8	54.9
CY22E	16145.7	9.4	279.6	11.8	64.4	42.6	86.3	56.4
CY23E	17822.4	10.4	314.2	12.4	57.3	37.9	83.1	57.5

Source: Company, ICICI Direct Research



## Financial Summary

Exhibit 33: Profit and los	s stateme	nt		₹ crore
(Year-end December)	CY20	CY21E	CY22E	CY23E
Total operating Income	13,350.0	14,829.5	16,218.2	17,902.1
Growth (%)	7.9	11.1	9.4	10.4
Raw Material Expenses	5,673.9	6,374.4	6,947.9	7,590.4
Employee Expenses	1,501.0	1,594.5	1,663.0	1,835.7
Marketing Expenses	1,371.1	0.0	0.0	0.0
Administrative Expenses	60.4	88.6	96.9	106.9
Other expenses	1,542.2	3,115.1	3,455.2	3,814.0
<b>Total Operating Expenditure</b>	10,148.5	11,172.5	12,162.9	13,347.0
EBITDA	3,201.5	3,656.9	4,055.2	4,555.1
Growth (%)	11.8	14.2	10.9	12.3
Depreciation	370.4	382.9	429.4	498.2
Interest	164.2	213.9	200.3	184.6
Other Income	145.9	161.8	178.0	178.0
PBT	2,812.8	3,221.9	3,603.5	4,050.3
Others	0.0	0.0	0.0	0.0
Total Tax	730.4	811.9	908.1	1,020.7
PAT	2,082.4	2,410.0	2,695.4	3,029.6
Growth (%)	5.7	15.7	11.8	12.4
EPS (₹)	216.0	249.9	279.6	314.2

Source: Company, ICICI Direct Research

Exhibit 34: Cash flow state	ment			₹ crore
(Year-end December)	CY20	CY21E	CY22E	CY23E
Profit after Tax	2,082.4	2,410.0	2,695.4	3,029.6
Add: Depreciation	370.4	382.9	429.4	498.2
(Inc)/dec in Current Assets	93.9	-1,168.5	-335.5	-407.0
Inc/(dec) in CL	345.0	186.6	246.1	298.6
CF from operating activities	2,891.8	1,811.0	3,035.5	3,419.4
(Inc)/dec in LT loans & adv	0.4	46.6	0.0	0.0
(Inc)/dec in other investments	2.8	-20.0	-20.0	-20.0
(Inc)/dec in Fixed Assets	-818.4	-920.0	-920.0	-820.0
Others	365.1	77.9	100.0	100.0
CF from investing activities	-478.9	-706.3	-840.0	-740.0
Issue/(Buy back) of Equity	0.0	0.0	0.0	0.0
Inc/(dec) in loan funds	44.3	0.0	0.0	0.0
Dividend paid & dividend tax	-1,889.8	-2,073.0	-2,314.1	-2,506.9
Inc/(dec) in Sec. premium	0.0	0.0	0.0	0.0
Others	281.9	0.0	0.0	0.0
CF from financing activities	-1,563.6	-2,073.0	-2,314.1	-2,506.9
Net Cash flow	849.2	-968.3	-118.6	172.5
Opening Cash	1,308.1	2,157.3	1,189.0	1,070.4
Closing Cash	2,157.3	1,189.0	1,070.4	1,242.8

Source: Company, ICICI Direct Research

Exhibit 35: Balance Sheet				₹ crore
(Year-end December)	CY20	CY21E	CY22E	CY23E
Liabilities				
Equity Capital	96.4	96.4	96.4	96.4
Reserve and Surplus	2,310.3	2,647.3	3,028.7	3,551.3
Total Shareholders funds	2,406.8	2,743.7	3,125.1	3,647.8
Total Debt	97.5	97.5	97.5	97.5
Deferred Tax Liability	0.0	0.0	0.0	0.0
Long Term Provisions	3,268.3	3,368.3	3,468.3	3,568.3
Total Liabilities	5,794.6	6,209.5	6,690.8	7,313.5
Assets				
Gross Block	3,951.0	4,851.0	5,751.0	6,551.0
Less: Acc Depreciation	1,771.5	2,154.4	2,583.8	3,082.0
Net Block	2,179.4	2,696.5	3,167.2	3,468.9
Capital WIP	638.6	658.6	678.6	698.6
Total Fixed Assets	2,818.0	3,355.1	3,845.7	4,167.5
LT Loans & Advances	46.6	0.0	0.0	0.0
Inventory	1,416.5	1,617.9	1,769.4	1,953.1
Debtors	164.9	161.8	176.9	195.3
Loans and Advances	13.2	161.8	176.9	195.3
Current Investments	820.6	1,642.2	1,795.9	1,982.4
Cash	2,157.3	1,189.0	1,070.4	1,242.8
Total Current Assets	4,572.5	4,772.7	4,989.6	5,569.0
Creditors	1,516.6	1,779.7	1,946.3	2,148.5
Provisions	106.0	242.7	265.4	293.0
Other Current Liabilities	870.0	656.7	713.5	782.4
Total Current Liabilities	2,492.6	2,679.1	2,925.3	3,223.9
Net Current Assets	2,079.9	2,093.5	2,064.3	2,345.2
Application of Funds	5,794.6	6,209.5	6,690.8	7,313.5

Source: Company, ICICI Direct Research

Exhibit 36: Key ratios				
(Year-end December)	CY20	CY21E	CY22E	CY23E
Per share data (₹)				
EPS	216.0	249.9	279.6	314.2
Cash EPS	254.4	289.7	324.1	365.9
BV	249.6	284.6	324.1	378.3
DPS	196.0	215.0	240.0	260.0
Cash Per Share	183.7	223.4	268.0	319.6
Operating Ratios (%)				
EBITDA Margin	24.0	24.7	25.0	25.4
PBT / Net Sales	21.2	21.8	22.3	22.7
PAT Margin	15.7	16.3	16.7	17.0
Inventory days	38.9	40.0	40.0	40.0
Debtor days	4.5	4.0	4.0	4.0
Creditor days	41.7	44.0	44.0	44.0
Return Ratios (%)				
RoE	86.5	87.8	86.3	83.1
RoCE	50.9	54.9	56.4	57.5
RoIC	93.5	74.2	72.6	74.8
Valuation Ratios (x)				
P/E	88.0	76.0	68.0	60.5
EV / EBITDA	56.6	49.8	45.0	40.0
EV / Net Sales	13.6	12.3	11.3	10.2
Market Cap / Sales	13.8	12.4	11.3	10.3
Price to Book Value	76.1	66.8	58.6	50.2
Solvency Ratios				
Debt/EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.1	0.1	0.0	0.0
Current Ratio	1.0	1.4	1.4	1.4
Quick Ratio	0.4	0.7	0.7	0.7

Source: Company, ICICI Direct Research

Exhibit 37: ICICI Direc	xhibit 37: ICICI Direct coverage universe (FMCG)																		
	CMP	TP		M Cap		EPS (₹)		P/E (x)			Price/Sales (x)			RoCE (%)			RoE (%)		
	(₹)	(₹)	Rating	(₹ Cr)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Colgate (COLPAL)	1,543	1,800	Buy	42,088	38.3	41.1	45.3	40.3	37.5	34.1	8.1	7.5	6.8	110.5	113.2	116.5	84.8	87.0	89.5
Dabur India (DABIND)	586	740	Buy	104,789	10.6	12.0	13.4	55.4	48.9	43.8	9.7	8.8	7.9	25.8	27.1	27.7	22.3	23.1	23.1
Hindustan Unilever (HINLEV)	2,393	2,750	Hold	582,416	39.3	44.3	48.6	60.8	54.0	49.3	11.4	10.5	9.6	25.0	27.6	29.5	19.5	21.5	23.0
ITC Limited (ITC)	223	260	Hold	293,108	12.0	13.7	15.3	18.5	16.3	14.6	5.5	5.0	4.5	31.4	34.1	36.0	24.2	26.2	27.6
Jyothy Lab (JYOLAB)	157	180	Hold	6,248	5.7	6.5	7.1	27.4	24.2	22.0	3.0	2.8	2.6	25.2	27.0	28.5	21.0	22.6	23.9
Marico (MARLIM)	570	685	Buy	73,541	10.2	11.4	12.5	56.0	49.9	45.7	7.6	7.3	6.8	43.0	47.3	49.2	38.7	41.2	42.7
Nestle (NESIND)	19,002	20,450	Hold	183,217	249.9	279.6	314.2	76.0	68.0	60.5	12.4	11.3	10.3	54.9	56.4	57.5	87.8	86.3	83.1
Tata Consumer Products (TAT	810	910	Buy	72,703	11.8	14.1	16.2	68.8	57.5	49.9	5.8	5.3	4.8	8.9	9.9	10.8	7.2	8.3	9.2
VST Industries (VSTIND)	3,298	3,700	Hold	5,334	223.1	245.8	277.0	14.8	13.4	11.9	4.6	4.2	3.9	44.2	47.7	55.1	32.8	35.7	41.2
Varun Beverage (VARBEV)	849	1,020	Buy	36,780	16.0	20.3	22.7	53.0	41.8	37.5	4.3	3.9	3.6	19.6	23.4	26.3	17.2	18.9	19.0
Zydus Wellness (ZYDWEL)	2,055	2,800	Buy	13,449	56.2	67.8	77.6	36.6	30.3	26.5	6.4	5.8	5.3	7.3	8.6	9.7	7.5	9.0	10.0

Source: Bloomberg, ICICI Direct Research

## **RATING RATIONALE**

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

#### ANALYST CERTIFICATION

I/We, Sanjay Manyal (MBA Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

## Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory
Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number –
INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its
various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect
of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavor to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.